Literature DB >> 30642447

Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer.

Matthew J Schuchert1, Daniel P Normolle2, Omar Awais3, Arjun Pennathur3, David O Wilson4, James D Luketich3, Rodney J Landreneau3.   

Abstract

OBJECTIVES: Anatomic lung resection provides the best opportunity for long-term survival in the setting of early-stage non-small cell lung cancer (NSCLC). However, 20-30% of patients develop recurrent disease following complete (R0) resection for Stage I disease. In the current study, we analyze the impact of patient, surgical and pathologic variables upon recurrence patterns following anatomic lung resection for clinical stage I NSCLC. PATIENTS AND METHODS: A total of 1132 patients (384 segmentectomies, 748 lobectomies) with clinical stage I NSCLC were evaluated. Predictors of recurrence were identified by proportional hazards regression. Differences in recurrence patterns between groups are illustrated by log rank tests applied to Kaplan-Maier estimates.
RESULTS: A total of 227 recurrences (20.0%) were recorded at a median follow-up of 36.8 months (65 locoregional, 155 distant). There was no significant difference in recurrence patterns when comparing segmentectomy and lobectomy. Multivariate analysis demonstrated that angiolymphatic invasion, tumor size, tumor grade and the presence of only mild-moderate tumor inflammation were independent predictors of recurrence risk.
CONCLUSIONS: Recurrence following anatomic lung resection is influenced predominantly by pathological variables (tumor size, tumor grade, angiolymphatic invasion, tumor inflammation). Optimization of surgical margin in relation to tumor size may improve outcomes. Extent of resection (segmentectomy vs. lobectomy) does not appear to have an impact on recurrence-free survival when adequate margins are obtained.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lobectomy; Multivariate analysis; Recurrence; Segmentectomy; Survival; Wedge resection

Year:  2018        PMID: 30642447     DOI: 10.1016/j.lungcan.2018.12.026

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Robotic versus thoracoscopic combined anatomic subsegmentectomy for early-stage lung cancer: early results of a cohort study.

Authors:  Zheng Jian; Chengqiang Li; Xijia Feng; Zhengxin Yin; Yichao Han; Yajie Zhang; Dingpei Han; Jie Xiang; Hecheng Li
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

2.  A clinical nomogram and heat map for assessing survival in patients with stage I non-small cell lung cancer after complete resection.

Authors:  Xun Cao; Yu-Zhen Zheng; Hong-Ying Liao; Xiang Guo; Yong Li; Zhen Wang; Li Zhang; Xu-Dong Wang; Xin Wang
Journal:  Ther Adv Med Oncol       Date:  2020-11-05       Impact factor: 8.168

Review 3.  How Bronchoscopic Dye Marking Can Help Minimally Invasive Lung Surgery.

Authors:  Matthieu Sarsam; Jean-Marc Baste; Luc Thiberville; Mathieu Salaun; Samy Lachkar
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

4.  Glutathione Peroxidase 3 as a Biomarker of Recurrence after Lung Cancer Surgery.

Authors:  Bo Gun Kho; Ha-Young Park; Hyun-Joo Cho; Cheol Kyu Park; Young-Chul Kim; Ju-Sik Yun; Sang-Yun Song; Kook-Joo Na; Yoo-Duk Choi; Seung-Won Lee; In-Jae Oh
Journal:  J Clin Med       Date:  2020-11-24       Impact factor: 4.241

5.  Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection.

Authors:  Yu-Jia Shen; Li-Qiang Qian; Zheng-Ping Ding; Qing-Quan Luo; Heng Zhao; Wu-Yan Xia; Yuan-Yuan Fu; Wen Feng; Qin Zhang; Wen Yu; Xu-Wei Cai; Xiao-Long Fu
Journal:  Front Oncol       Date:  2021-09-01       Impact factor: 6.244

6.  CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.

Authors:  Mingjun Li; Qianqian Wang; Xiaofei Zhang; Ningning Yan; Xingya Li
Journal:  Cell Cycle       Date:  2021-06-07       Impact factor: 5.173

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.